For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), ...
For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), ...
Two doses of 52-week nerandomilast reduced FVC decline vs. placebo in the subgroup of U.S. adults with idiopathic pulmonary ...
In idiopathic pulmonary fibrosis, the lung tissue thickens and stiffens through proliferation of fibroblasts and invasion by inflammatory cells. One of the drivers of these processes is the enzyme ...
Columnist Sam Kirton explains when the new FDA-approved IPF treatment Jascayd might be made available to patients.
Brainomix said its e-Lung software detects lung scarring and may help with earlier diagnosis and more accurate monitoring of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback